Humacyte, Inc. — Director's Dealing 2022

Sep 20, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2022-09-19

Reporting Person: Cao Yang (Chief Regulatory Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-19	Stock Options (right to buy)	$3.73	A	145000	Acquired	2032-09-19	Common Stock (145000.0)	Direct

Footnotes

F1: The first 25% of the option becomes exercisable on September 19, 2023, after which 1/48 of the option will become exercisable on the 19th of each month through September 19, 2026.